[{"orgOrder":0,"company":"Ajinomoto Company","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Ajinomoto Company","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Ajinomoto Company \/ Exelixis","highestDevelopmentStatusID":"2","companyTruncated":"Ajinomoto Company \/ Exelixis"},{"orgOrder":0,"company":"Ajinomoto Company","sponsor":"Citius Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Denileukin Diftitox-cxdl","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Ajinomoto Company","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ajinomoto Company \/ Ajinomoto Company","highestDevelopmentStatusID":"10","companyTruncated":"Ajinomoto Company \/ Ajinomoto Company"}]

Find Clinical Drug Pipeline Developments & Deals by Ajinomoto Company

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : LYMPHIR (denileukin diftitox-cxdl) is a recombinant fusion protein that combines the interleukin-2 (IL-2) receptor binding domain with diphtheria toxin fragments.

                          Brand Name : Lymphir

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          July 29, 2023

                          Lead Product(s) : Denileukin Diftitox-cxdl

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Recipient : Citius Pharmaceuticals

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : As part of the license agreement, Exelixis will have the right to use the AJICAP technology to support its aim of advancing multiple Antibody-drug Conjugates with the potential for higher efficacy and lower toxicity than currently available options.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          January 10, 2023

                          Lead Product(s) : Antibody-drug Conjugate

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Exelixis

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank